Effects of probucol combined with argatroban on NIHSS and BI scores and coagulation function in patients with perforator artery cerebral infarction
Objective:To retrospectively analyze the efficacy of probucol combined with argatroban in treating perfora artery cerebral infarction(PACI).Methods:A total of 208 PACI patients admitted to our hospital from September 2021 to June 2023 were divided into two groups based on different treatment regimens,with 104 patients in each group.The control group was given argatroban(initial dose of 60 mg·d-1 for 24 hours of intravenous infusion,adjusted to 10 mg on the third day,for 3 hours of intravenous infusion,twice a day).The combination group was given the control group plus probucol(250 mg orally,twice a day).After 7 days of treatment,prothrombin time(PT),activated partial thromboplastin time(APTT),D-dimer(D-D),and fibrinogen(FIB)were detected using a high-speed fully automated coagulation tester.The messenger RNA(mRNA)expression levels of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3),cysteinyl aspartate specific proteinase 1(Caspase-1),interleukin-1β(IL-1β)were detected using fluorescence quantitative reverse transcription polymerase chain reaction(PCR),the neurological function was evaluated using the National Institutes of Health Stroke Scale(NIHSS),and the quality of life was evaluated using the Barthel index(BI).Results:The total effective rate of the combined group was higher than that of the control group(P<0.05).After treatment,the PT and APTT levels in the combination group were higher than those in the control group,while the levels of D-D,FIB,NLRP3,Caspase-1,and IL-1β mRNA were lower than those in the control group(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Argatroban combined with probucol is more effective in the treatment of PACI.
ProbucolArgatrobanPerforator artery cerebral infarctionCoagulation functionNeural function
NETL
NSTL
万方数据
